Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro

Thrombosis Research

Volumn 124, Issue 3, 2009, Pages 364-367

  Kaplinska, Katarzyna ^a   Rozalski, Marek ^a   Krajewska, Urszula ^a   Mielicki, Wojciech P ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

cancer procoagulant; fibrin clot; procoagulant activity; tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; CANCER PROCOAGULANT; CELL EXTRACT; CELL PROTEIN; MONOCLONAL ANTIBODY; THROMBOPLASTIN;

ARTICLE; CANCER CELL; CELL CULTURE; CELL LINE; CELL LYSATE; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; WESTERN BLOTTING; WHOLE CELL;

ANIMALS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; FACTOR X; MELANOMA; NEOPLASM PROTEINS; THROMBOPLASTIN;

EID: 67649831392     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.03.009     Document Type: Article

References (47)

1. Loreto M.F., De Martinis M., Corsi M.P., Modesti M., and Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol Oncol Res 6 (2000) 301-312
2. Caine G.J., Stonelake P.S., Lip G.Y.H., and Kehoe S.T. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4 (2002) 465-473
3. De Lucia D., De Vita F., Orditura M., Renis V., Belli A., Conte M., et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori 83 (1997) 948-952
4. Belting M., Ahamed J., and Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 25 (2005) 1545-1550
5. Wojtukiewicz M.Z., Zacharski L.R., Memoli V.A., Kisiel W., Kudryk B.J., Rousseau S.M., et al. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Path 93 (1990) 516-521
6. Shoji M., Hancock W.W., Abe K., Micko C., Casper K.A., Baine R.M., et al. Activation of coagulation and angiogenesis in cancer. Am J Pathol 152 (1998) 399-411
7. Bardos H., Juhasz A., Repassy G., and Adany R. Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx. Thromb Haemost 80 (1998) 767-772
8. Biggerstaff J.P., Seth N., Amirkhosriavi A., Amaya M., Fogarty S., Meyer T.V., et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 17 (1999) 723-730
9. Palumbo J.S., Potter J.M., Kaplan L.S., Talmage K., Jackson D.G., and Degen J.L. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62 (2002) 6966-6972
10. Biggerstaff J.P., Weidow B., Vidosh J., Dexheimer J., Patel S., and Patel P. Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis. Thromb J 4 (2006) 12
11. Suzuki M., Inufusa H., Yamamoto S., Hamada T., Aga M., Ando O., et al. Ley glycolipid acts as a co-factor for tumor procoagulant activity. Int J Cancer 73 (1997) 903-909
12. Inufusa H., Adachi T., Suzuki M., Ando O., Ohta T., Kurimoto M., et al. Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines. Cancer 82 (1998) 1563-1569
13. Ogiichi T., Hirashima Y., Nakamura S., Endo S., Kurimoto M., and Takaku A. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neurooncol 46 (2000) 1-9
14. Kazmierczak M., Lewandowski K., Wojtukiewicz M.Z., Turowiecka Z., Kolacz E., Lojko A., et al. Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrynolysis 16 (2005) 543-547
15. Mielicki W.P., and Gordon S.G. Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. Blood Coagul Fibrynolysis 4 (1993) 441-446
16. Donati M.B., Gambacorti-Passerini C., Casali B., Falanga A., Vannotti P., Fossati G., et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 46 (1986) 6471-6474
17. Gordon S.G., and Cross B.A. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res 50 (1990) 6229-6234
18. Moore W.R. The purification and properties of cancer procoagulant from murine tumors. Biochem Biophys Res Com 184 (1992) 819-824
19. Gordon S.G., Gilbert L.C., and Lewis B.J. Analysis of procoagulant activity of intact cells from tissue culture. Thromb Res 26 (1982) 379-387
20. Gordon S.G., and Lewis B.J. Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts. Cancer Res 38 (1978) 2467-2472
21. Gordon S.G., and Cross B.A. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 67 (1981) 1665-1671
22. Gordon S.G., Hasiba U., Cross B.A., Poole M.A., and Falanga A. Cysteine proteinase procoagulant from amnion-chorion. Blood 66 (1985) 1261-1265
23. Kamocka M., Rozalski M., Krajewska U., Wierzbicki R., and Mielicki W.P. Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. Cancer Lett 222 (2005) 89-94
24. Olas B., Wachowicz B., and Mielicki W.P. Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant. Platelets 12 (2001) 431-435
25. Sampson M.T., and Kakkar A.K. Coagulation proteases and human cancer. Biochem Soc Trans 30 (2002) 201-207
26. Haas S.L., Jesnowski R., Steiner M., Hummel F., Ringel J., Burstein C., et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 12 (2006) 4843-4849
27. Bromberg M.E., Sundaram R., homer R.J., Garen A., and Konigsberg W.H. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 82 (1999) 88-92
28. Kozwich D.L., Kramer L.C., Mielicki W.P., Fotopoulos S.S., and Gordon S.G. Application of cancer procoagulant as an early detection tumor marker. Cancer 74 (1994) 1367-1376
29. Rucinska M., Furman M., Skrzydlewski Z., and Zaremba E. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Acta Biochim Pol 44 (1997) 109-112
30. Gordon S.G., and Mielicki W.P. Cancer procoagulant: a factor X-activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolyzis 8 (1997) 73-86
31. Abe K., Shoji M., Chen J., Bierhaus A., Danave I., Micko C., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci 96 (1999) 8663-8668
32. Mielicki W.P., and Sobolewska M. Cancer procoagulant (EC 3.4.22.26): the kinetics of its inhibition by E-64 and modulation of the activity by cadmium, cooper and tin ions. Cancer Res Therapy Ctrl 11 (2001) 135-141
33. Mielicki W.P., Kozwich D.L., Kramer L.C., and Gordon S.G. Effect of divalent ions on the activity of cancer procoagulant. Arch Biochem Biophys 314 (1994) 165-170
34. Falanga A., Consonni R., Marchetti M., Locatelli G., Garattini E., Gambacorti Passerini C., et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 92 (1998) 143-151
35. Magdolen V., Albrecht S., Kotzsch M., Haller C., Burgle M., Jacob U., et al. Immunological and functional analyses of the extracellular domain of human tissue factor. Biol Chem 379 (1998) 157-165
36. Doolittle R.F., Schubert D., and Schwarzt S.A. Amino acid sequence studies on artiodactyl fibrinopeptides. I. Dromadery camel, mule deer, and cape buffalo. Arch Biochem Biophys 118 (1967) 456-467
37. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophag T4. Nature 227 (1970) 680-685
38. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 50 (2004) 187-196
39. Falanga A., and Donati M.B. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 73 (2001) 137-144
40. Tenderenda M., Mielicki W.P., Berner J., and Rutkowski P. Analysis of selected blood coagulation parameters and presence of cancer procoagulant (EC3.4.22.26) in patients with malignant neoplasms treated by surgery. Med Sci Monitor 5 (1999) 123-126
41. Pickering W., Gray E., Goodall A.H., Ran S., Thorpe P.E., and Barrowcliffe T.W. Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. J Thromb Haemost 2 (2004) 459-467
42. Kazama Y., Hamamoto T., Foster D.C., and Kisiel W. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 270 (1995) 66-72
43. Mielicki W., and Wierzbicki R. Cancer procoagulant in serum of rats during development of experimental epithelioma. Int J Cancer 45 (1990) 125-126
44. Ito N., DeMarco R.A., Mailliard R.B., Han J., Rabinowich H., Kalinski P., et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81 (2007) 75-83
45. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001) 1659-1665
46. Kleinfeld A.M., and Okada C. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing. J Lipid Res 46 (2005) 1983-1990
47. Gunji Y., and Gorelik E. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48 (1988) 5216-5221